Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+cancers Meeting Abstract
| Authors: | Fu, S.; Nabell, L.; Pearson, A. T.; Leidner, R.; Adkins, D.; Posner, M. R.; Nieva, J. J.; Richardson, D. L.; Pimentel, A.; Goel, S.; Wong, S. J.; Ho, A. L.; Rosenberg, A.; Taylor, M. H.; Abdul-Karim, R.; Iacobucci, C.; Qing, X.; Katchar, K.; Schlienger, K.; Pfister, D. G. |
| Abstract Title: | Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+cancers |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300741 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.2517 |
| Notes: | Meeting Abstract: 2517 -- This meeting was also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work